EMILY MCCLANAHAN: Open Payments
NPI 1952066672 · LEES SUMMIT, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,309 in 72 payments from 10 companies in 2025. Trend: 2023 $1,238 · 2024 $1,792 · 2025 $1,309
Food & beverage: $1,225Education: $84
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 22 | $337 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 14 | $235 |
| Janssen Biotech, Inc. | 8 | $229 |
| Regeneron Healthcare Solutions, Inc. | 9 | $193 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $155 |
| Ardelyx, Inc. | 3 | $59 |
| Lilly USA, LLC | 2 | $38 |
| Ipsen Biopharmaceuticals, Inc | 1 | $25 |
| Madrigal Pharmaceuticals | 1 | $20 |
| Phathom Pharmaceuticals, Inc. | 2 | $16 |
Products named: XIFAXAN, TREMFYA, DUPIXENT, RINVOQ, LINZESS, ENTYVIO, IBSRELA, EOHILIA.
Industry payments across MO — which companies pay providers there.
